APA (7th ed.) Citation

K, T., A, W., Y, Z., S, W., C, W., J, L., . . . H, C. (2025). Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: A systematic review and meta-analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(1), 196. https://doi.org/10.1007/s12094-024-03529-x

Chicago Style (17th ed.) Citation

K, Tan, et al. "Safety and Efficacy of Restarting Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients Following Immune-related Adverse Events: A Systematic Review and Meta-analysis." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 27, no. 1 (2025): 196. https://doi.org/10.1007/s12094-024-03529-x.

MLA (9th ed.) Citation

K, Tan, et al. "Safety and Efficacy of Restarting Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients Following Immune-related Adverse Events: A Systematic Review and Meta-analysis." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 27, no. 1, 2025, p. 196, https://doi.org/10.1007/s12094-024-03529-x.